Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2003-03-25
2009-08-25
Kelly, Robert M (Department: 1633)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C424S093100, C435S320100, C536S023100, C536S023400, C536S024500, C536S024100
Reexamination Certificate
active
07579326
ABSTRACT:
Disclosed is a novel inducible expression system characterized by undetectable biological effect in the absence of an inducer, but which exhibits efficient inducibility in the presence of an inducer.
REFERENCES:
patent: 4703008 (1987-10-01), Lin
patent: 4835260 (1989-05-01), Shoemaker
patent: 4954437 (1990-09-01), Beck et al.
patent: 5298422 (1994-03-01), Schwartz et al.
patent: 5364791 (1994-11-01), Vegeto et al.
patent: 5439440 (1995-08-01), Hofmann
patent: 5457089 (1995-10-01), Fibi et al.
patent: 5580853 (1996-12-01), Sytkowski
patent: 5614184 (1997-03-01), Sytkowski et al.
patent: 5688679 (1997-11-01), Powell
patent: 5704908 (1998-01-01), Hofmann et al.
patent: 5846528 (1998-12-01), Podsakoff et al.
patent: 5874534 (1999-02-01), Vegeto et al.
patent: 5888772 (1999-03-01), Okasinski et al.
patent: 5935934 (1999-08-01), Vegeto et al.
patent: 6093699 (2000-07-01), Sehon et al.
patent: 6153407 (2000-11-01), Sytkowski et al.
patent: 0232034 (1987-08-01), None
patent: WO 85/02610 (1985-06-01), None
patent: WO 90/07517 (1990-07-01), None
patent: WO 90/14356 (1990-11-01), None
patent: WO 93/23431 (1993-11-01), None
patent: WO 96/40911 (1996-12-01), None
patent: WO 97/44447 (1997-11-01), None
patent: WO 98/18925 (1998-05-01), None
patent: WO 99/06562 (1999-02-01), None
patent: WO 99/11801 (1999-03-01), None
patent: WO 99/32145 (1999-07-01), None
patent: WO 00/09713 (2000-02-01), None
patent: WO00/30618 (2000-05-01), None
patent: WO 00/31286 (2000-06-01), None
patent: WO 01/66149 (2001-09-01), None
Nordstrom (2003) Steroids, 68: 1085-94.
Rudinger (1976) Peptide Hormones, University Park Press, Baltimore, MD. pp. 1-7.
Bowie, (1990) Science 247: 1306-10.
Whelan et al., “Generation of Estrogen Receptor Mutants with Altered Ligand Specificity for Use in Establishing a Regulatable Gene Expression System,” J. Steroid Biochem. Molec. Biol. vol. 58, No. 1, pp. 3-12, 1996.
Braselmann, et al., “A Selective Transcriptional Induction System for Mammalian Cells Based on Ga14-Estrogen Receptor Fusion Proteins,” Proc. Nat Acad. Sci. USA vol. 90, pp. 1657-1661, Mar. 1993.
Sollerbrant, K., Akusjarvi, G, Linder, S., Svensson, C. The DNA binding domains of the yeast Gal4 and human c-jun transcription factors interact through the zinc-finger and bZIP motifs. Nucleic Acids Research 23 (1995) 588-594.
Arici A., Marchburn, P., MacDonald, P., Dombrowski, R. Progesterone metabolism in human endometrial stromal and gland cells in culture. Steroids 64 (1999) 530-534.
Abruzzese, RV et al, Ligand-Dependent Regulation of Plasmid-Based transgene Expression in Vivo, Human Gene Therapy, Jun. 10, 1999, 1499-1507, vol. 10, Mary Ann Liebert, Inc.
Abruzzese, RV et al, Ligand-Dependent Regulation of Vascular Endothelial Growth Factor and Erythropoietin Expression by a Plasmid-Based Autoinducible GeneSwitch System, Molecular Therapy, Sep. 2000, 276-287, vol. 2.
Aurisicchio, L et al, Liver-Specific Alpha 2 Interferon Gene Expression results in Protection from Induced Hepatitis, Journal of Virology, May 2000, 4816-4823, vol. 74 No. 10.
Baleja, JD et al, Solution structure of the DNA-binding domain of Cd2-GAL4 fromS. cerevisiae, Nature, Apr. 2, 1992, 450-453, vol. 356.
Bohl, D and Jean-Michel Heard, Delivering Erythropoietin through Genetically Engineered Cells, Journal of Am Soc Nephrol, 2000, S159-S162, vol. 11.
Burnstein, KL et al, Intragenic Sequences of the Human Glucocorticoid Receptor Complementary DNA Mediate Hormone-Inducible Receptor Messenger RNA Down-Regulation through Multiple Mechanisms, Molecular Endocrinology, 1994, 1764-1773, vol. 8.
Byravan , S et al, Two Point Mutations in the Hormone-Binding Domain of the Mouse Glucocorticoid Receptor That Dramatically Reduce Its Function, Molecular Endocrinology, 1991, 752-758, vol. 5.
Chen, D and Michael R. Stallcup, The Hormone-binding Role of 2 Cysteines Near the C Terminus of The Mouse Glucocorticoid Receptor, Journal of Biological Chemistry, Mar. 18, 1994, 7914-7918, vol. 269 No. 11.
Dahlman-Wright, K et al, Delineation of a small region within the major transactivation domain of the human glucocorticoid receptor that mediates transactivation of gene expression, Proc. Natl. Acad. Sci., Mar. 1994, 1619-1623, vol. 91.
Dai Y et al , Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: Tolerization of factor IX and Vector antigens allows for long-term expression, PNAS 92 (1995) 1401.
Ferkol , T et al, Regulation of the phosphoenolpyruvate carboxykinase/human factor IX gene introduced onto the livers of adult rats by receptor-mediated gene transfer, J. FASEB, 1993, 1081-1091, vol. 7.
Fields, PA. et al, Role of Vector in Activation of T Cell Subsets in Immune Responses against the Secreted Transgene Product Factor IX, Molecuar Therapy, Mar. 2000, 225-235, vol. 1 No. 3.
Glue, P et al, A Dose-Ranging Study of Pegylated Interferon Alfa-2b and Ribavirin in Chronic Hepatitis C, Hepatology, 2000, 647-653, vol. 32.
Glue, P et al, Pegylated interferon-alpha2b: Pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data, Clin Pharmacol Ther, 2000, 556-567, vol. 68.
Herzog, R W et al, Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector, Nature Medicine, Jan. 1999, 56-63, vol. 5 No. 1.
Hwang, JJ et al, Characteristics of the transcription activation function and the DNA binding domain of transcriptional enhancer factor-1, J. Embo, Jun. 1993, 2337-2348, vol. 12 No. 6.
Jacobs, K et al, Isolation and characterization of genomic and cDNA clones of human erythropoietin, Nature, Feb. 1985, 806-812, vol. 313.
Jenster, G et al, Steroid erceptor induction of gene transcription: A two-step model, Proc. Natl. Acad. Sci., Jul. 1997, 7879-7884, vol. 94.
Kessler, PD et al, Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein, Proc. Natl. Acad. Sci., Nov. 1996, 14082-14087, vol. 93.
Kloosterboer, HJ et al, Pharmacological Properties of a New Selective Antiprogestagen: Org 33628, Ann NY Acad Sci, 1995, 192-201, vol. 761.
Lemieux, P et al, A combination of poloxamers increases gene expression of plasmid DNA in skeletal muscle, Gene Therapy, 2000, 986-991, vol. 7.
Lin, F-K et al, Cloning and expression of the human erythropoietin gene, Proc. Natl. Acad. Sci., Nov. 1985, 7580-7584, vol. 82.
MacColl, GS et al, Using skeletal muscle as an artificial endocrine tissue, Journal of Endocrinology, 1999, 1-9, vol. 162.
Macias, MP et al, Cellular or Viral Protein Binding to a Cytomegalovirus Promoter Transcription Initiation Site: Effects on Transcription, Journal of Virology, Jun. 1996, 3628-3635, vol. 70 No. 6.
Mahato, RI et al, Biodistribution and Gene Expression of Lipid/Plasmid Complexes after Systemic Administration, Human Gene Therapy, Sep. 20, 1998, 2083-2099, vol. 9.
Mehta, V et al, Long-term, Drug-Dependent Regulation of Erythropoietin and Hematocrit in Mice Following Delivery of Plasmids to Skeletal Muscle, Experimental Hematology, Jul. 2000, 63, vol. 28 No. 7 supp.1.
Michou, AL et al, Adenovirus-mediated gene transfer: influence of transgene, mouse strain and tyoe of immune response on persistence of transgene expression, Gene Therapy, 1977, 472-482, vol. 4.
Milhon, J et al, Identification of Amino Acids in the t2-Region of the Mouse Glucocorticoid Receptor That Contribute to Hormone Binding and Transcriptional Activation, Molecular Endocrinology, 1997, 1795-1805, vol. 11.
Moruchi, H et al, Hydrophobic cluster analysis predicts an amino-terminal domain of varicella-zoster virus open reading frame 10 required for transcriptional activation, Proc. Natl. Acad. Sci., Sep. 1995, 9333-9337, vol. 92.
Muller, M et al, Multiple Domains of the Glucocorticoid Receptor Involved in Synergism with the CACCC Box Factor(s), Molecular Endocrinology, 1991, 1498-1503, vol. 5.
Oligino, T et al, Drug inducible transgene expression in brain using a herpes simplex virus vector, Gene Therapy, 1998, 491-495, vol. 5.
Pan, T and Joseph E. Coleman, GAL4 transcriptional factor is not a “zinc fingerȁ
Abruzzese Ronald V
Fewell Jason
Mehta Vidya
Nordstrom Jeffrey L
O'Malley Bert
Baylor College of Medicine
Genetronics Inc.
Kelly Robert M
Wong Cabello Lutsch Rutherford & Brucculeri LLP
LandOfFree
Gene switch systems employing regulators with decreased... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Gene switch systems employing regulators with decreased..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Gene switch systems employing regulators with decreased... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4065278